SCHEMBL4773843

SCHEMBL4773843

O=C([C@@H]1CCCN1OC(=O)C(F)(F)F)N(CCCN1CCC(Cc2ccccc2)CC1)Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.49
KDM4E B2RXH2 2/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
CCR5 P51681 1/20 0.45
CCR3 P51677 2/20 0.43
SIGMAR1 Q99720 2/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
HRH3 Q9Y5N1 1/20 0.43
SLC6A2 P23975 1/20 0.43
SLC6A3 Q01959 1/20 0.43
ALDH1A1 P00352 1/20 0.42
TMEM97 Q5BJF2 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4775520 0.86 GAA (0.57) OPRM1KDM4ELMNAGAACCR5
Trifluoroacetic Acid SCHEMBL4777983 0.81 OPRM1 (0.48) OPRM1KDM4ELMNAGAACCR5
SCHEMBL7163438 0.77 OPRM1 (0.47) OPRM1KDM4ELMNAGAACCR5
SCHEMBL6056771 0.77 OPRM1 (0.53) OPRM1CCR3SIGMAR1HRH3SLC6A2
Trifluoroacetic Acid SCHEMBL4773841 0.77 OPRM1 (0.51) OPRM1KDM4ELMNAGAACCR5
Trifluoroacetic Acid SCHEMBL4775516 0.77 GAA (0.55) OPRM1KDM4ELMNAGAACCR5
Trifluoroacetic Acid SCHEMBL4777069 0.76 CCR5 (0.68) OPRM1KDM4ELMNAGAACCR5
Trifluoroacetic Acid SCHEMBL6056693 0.76 OPRM1 (0.56) OPRM1LMNACCR5CCR3SIGMAR1
Trifluoroacetic Acid SCHEMBL6056668 0.75 CCR3 (0.55) OPRM1CCR3SIGMAR1MEN1KMT2A
Trifluoroacetic Acid SCHEMBL6056707 0.74 OPRM1 (0.52) OPRM1LMNAGAACCR5CCR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed
EP-1220842-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2002-07-10 EP disclosed
WO-2001025200-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 OPRM1 9/4885KDM4E 2791/4885LMNA 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.